Enlivex Therapeutics
ENLV
ENLV
15 hedge funds and large institutions have $1.24M invested in Enlivex Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
19% less call options, than puts
Call options by funds: $188K | Put options by funds: $232K
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
15
Holding in Top 10
–
Calls
$188K
Puts
$232K
Top Buyers
| 1 | +$184K | |
| 2 | +$152K | |
| 3 | +$69K | |
| 4 |
Renaissance Technologies
New York
|
+$29.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$27.4K |
Top Sellers
| 1 | -$63.7K | |
| 2 | -$35.1K | |
| 3 | -$12.8K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.25K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$718 |